Citations

Showing 10 of 108073 citations.

Relationship Between Gastric Emptying and Diurnal Glycemic Control in Type 1 Diabetes Mellitus: A Randomized Trial
Parthasarathy, Gopanandan , Kudva, Yogish C. , Low, Phillip A. , Camilleri, Michael , Basu, Ananda , Bharucha, Adil E.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | November 23, 2016 | Volume: 102 | Issue: 2 | Pages: 398-406

10.1210/jc.2016-2809 | PMID 27880079 Get It

PTH-072 Corticosteroid Dose Reduction in Ulcerative Colitis Patients Treated with Vedolizumab
Loftus, Edward V. , Sandborn, William J. , James, A. , Xu, Jing , Abhyankar, B, Siegel, Corey A , Panaccione, Remo , Smyth, Michael D.L. , Loftus, Edward V

Mayo Clinic

BSG 2016 | November 23, 2016 | Volume: No volume available | Issue: No issue available | Pages: A254.2-A255

10.1136/gutjnl-2016-312388.478 Get It

PWE-020 Corticosteroid Dose Reduction with Vedolizumab Treatment of Crohn’s Disease
Loftus, Edward V. , Sandborn, W., James, A. , Xu, Jing , Abhyankar, B, Siegel, Corey A , Panaccione, Remo , Smyth, Michael D.L. , Loftus, Edward V

Mayo Clinic

BSG 2016 | November 23, 2016 | Volume: No volume available | Issue: No issue available | Pages: A147.1-A147

10.1136/gutjnl-2016-312388.265 Get It

PTU-137 Enhanced Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by History and Diagnostic Evaluation
Sood, Ruchit , Camilleri, Michael , Gracie, DJ, Gold, M S, To, N., Ford, Alexander C. , Law, Graham Richard , Ford, Alexander C

Mayo Clinic

BSG 2016 | November 23, 2016 | Volume: No volume available | Issue: No issue available | Pages: A125.1-A125

10.1136/gutjnl-2016-312388.223 Get It

PTU-133 Effect of Eluxadoline on Abdominal and Bowel Symptoms Over Time in Phase 3 Clinical Trials in Patients with Irritable Bowel Syndrome with Diarrhoea (IBS-D)
Harris, LA, Lucak, Susan, Dove, LS, Covington, PS, Chang, Lin

Mayo Clinic

BSG 2016 | November 23, 2016 | Volume: No volume available | Issue: No issue available | Pages: A122.2-A123

10.1136/gutjnl-2016-312388.219 Get It

Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States
Pine, Alexander B. , Sekeres, Mikkael A. , Zelterman, Daniel , Komrokji, Rami S. , Litzow, Mark R. , Luger, Selina M. , Stone, Richard M. , Garcia‐Manero, Guillermo , Lee, Alfred Ian , Barbarotta, Lisa, Kasberg, Stephanie, Gore, Steven D. , Zeidan, Amer M. , Lee, Eun‐Ju , Steensma, David P. , Prébet, Thomas , Dezern, Amy Elizabeth , Erba, Harry Paul , Podoltsev, Nikolai , Hendrickson, Jeanne E. , Komrokji, Rami S , Sekeres, Mikkael A , Zeidan, Amer M

Mayo Clinic

Transfusion | November 23, 2016 | Volume: 57 | Issue: 2 | Pages: 289-295

10.1111/trf.13934 | PMID 27878822 Get It

BACKGROUNDTransfusion of blood products is a key component of the supportive management in patients with acute leukemia (AL). However high‐quality trial evidence and clinical outcome data to support specific transfusion goals for blood products for patients with AL remain limited leading to diverse transfusion practices. The primary objective of this study was to determine the spectrum of transfusion patterns in a variety of care settings among providers who treat AL patients.STUDY DESIGN AND METHODSA 31‐question survey queried providers caring for AL patients about the existence of institutional guidelines for transfusion of blood products, transfusion triggers for hemoglobin (Hb), platelets (PLTs), and fibrinogen in various settings including inpatient and outpatient and before procedures.RESULTSWe analyzed 130 responses and identified divergent transfusion Hb goals in hospitalized and ambulatory patients, fibrinogen goals for cryoprecipitate transfusions, and variation in practice for use of certain PLTs and red blood cell products. The least variable transfusion patterns were reported for PLT goals in thrombocytopenia and in the setting of invasive procedures such as bone marrow biopsy and lumbar punctures.CONCLUSIONSThis survey confirmed wide variations in blood product transfusion practices across several clinical scenarios in patients with AL. The findings emphasized the need for large prospective randomized trials to develop standardized evidence‐based guidelines for blood product transfusions in patients with AL with the goal of limiting unnecessary transfusions without compromising outcomes.
Presence of intraepithelial food antigen in patients with active eosinophilic oesophagitis
Marietta, Eric, Geno, D. M., Smyrk, Thomas C. , Becker, Alexa , Alexander, Jeffrey A. , Camilleri, Michael , Katzka, David A. , Murray, Joseph A.

Mayo Clinic

Alimentary Pharmacology & Therapeutics | November 23, 2016 | Volume: 45 | Issue: 3 | Pages: 427-433

10.1111/apt.13877 | PMID 27878833 Get It

SummaryBackgroundAlthough eosinophilic oesophagitis (EoE) is putatively mediated by an abnormal response to food antigen, the oesophagus is considered relatively impermeable to large molecules.AimTo assess whether food antigens penetrate the oesophageal mucosa in patients with EoE.MethodsAnti‐gliadin staining was performed in three groups: active EoE, inactive EoE and EoE patients on a low or gluten free diet. To appraise the specificity of our results, we also performed gliadin staining on six patients without oesophageal disease who were consuming gluten. The groups with EoE on gluten also underwent endoscopic infusion with gluten containing soy sauce and repeat biopsies during the endoscopy. We measured eosinophil density, dilated intercellular spaces (on a 0–4+ scale) and gliadin in oesophageal mucosa by immunofluorescence.ResultsPatients with active EoE had significantly greater epithelial density of anti‐gliadin staining when compared to inactive EoE (P < 0.0065) and gluten‐free patients (P < 0.0008) at baseline and after soy infusion. Gliadin was not detected in non‐EoE control patients. The distribution of gliadin was both cytoplasmic and nuclear. There was good correlation of dilated intercellular spaces grade and total gliadin staining intensity (r = 0.577, P = 0.0077). Acute oesophageal perfusion of a commercial gliadin‐rich soy sauce did not lead to an increase in gliadin staining in active or inactive EoE.ConclusionThese findings suggest, although do not prove, that antigen penetration in active eosinophilic oesophagitis might be facilitated by impairment of epithelial integrity.
HARNESSING BIG DATA FOR PRECISION MEDICINE: INFRASTRUCTURES AND APPLICATIONS
Yu, Kun‐Hsing , Goldfeder, Rachel L. , Zhang, Qiangfeng Cliff , Yu, Kun‐Hsing , Hart, Steven N. , Parker, Stephen C.J. , Snyder, Michael

Mayo Clinic

Biocomputing 2017 | November 23, 2016 | Volume: No volume available | Issue: No issue available | Pages: 635-639

10.1142/9789813207813_0058 | PMID 27897013 Get It

Eosinophilic fasciitis with subjacent myositis
Whitlock, Julia B., Dimberg, Elliot L., Selcen, Duygu , Rubin, Devon I.

Mayo Clinic

Muscle & Nerve | November 22, 2016 | Volume: 56 | Issue: 3 | Pages: 525-529

10.1002/mus.25492 | PMID 27875630 Get It

ABSTRACTIntroductionEosinophilic fasciitis (EF) is a rare disorder that can present with muscle symptoms that mimic other neuromuscular diseases.MethodsWe report the case of a 43‐year‐old woman with chronic muscle aches, tightness, and stiffness with hypertrophied, well‐defined muscles despite physical inactivity, and thickened skin with reduced elasticity and discoloration.ResultsExcept for mild peripheral eosinophilia, laboratory studies, including blood count, electrolytes, paraneoplastic panel, muscle enzymes, thyroid function, and serum protein electrophoresis, were normal. Nerve conduction studies and needle electromyography were normal. Magnetic resonance imaging of the thighs demonstrated superficial and deep fascial thickening with T2 hyperintensity and post‐gadolinium enhancement. Fascial and muscle biopsy demonstrated an inflammatory exudate in the perimysium and endomysium with fragmented perimysial connective tissue and thickened, inflamed fascia. EF was diagnosed. The patient was treated with methotrexate and prednisone followed by improvement of muscle stiffness and tightness.ConclusionEF should be considered when patients present with muscle pain or enlarged muscles. Muscle Nerve 56: 525–529, 2017
Elevated Modified Shock Index Within 24 Hours of ICU Admission Is an Early Indicator of Mortality in the Critically Ill
Seisa, Mohamed O. , Heise, Katherine J., Schroeder, Darrell R. , Weister, Timothy J. , Diedrich, Daniel A. , Smischney, Nathan J. , Schroeder, Darrell

Mayo Clinic

Journal of Intensive Care Medicine | November 22, 2016 | Volume: 33 | Issue: 10 | Pages: 582-588

10.1177/0885066616679606 | PMID 27879296 Get It

Purpose: To assess whether exposure to modified shock index (MSI) in the first 24 hours of intensive care unit (ICU) admission is associated with increased in-hospital mortality. Methods: Adult critically ill patients were included in a case–control design with 1:2 matching. Cases (death) and controls (alive) were abstracted by a reviewer blinded to exposure status (MSI). Cases were matched to controls on 3 factors—age, end-stage renal disease, and ICU admission diagnosis. Results: Eighty-three cases and 159 controls were included. On univariate analysis, lorazepam administration (odds ratio [OR]: 5.75, confidence interval [CI] = 2.28-14.47; P ≤ .01), shock requiring vasopressors (OR: 3.62, CI = 1.77-7.40; P ≤ .01), maximum MSI (OR: 2.77 per unit, CI = 1.63-4.71; P ≤ .001), and elevated acute physiologic and chronic health evaluation (APACHE) III score at 1 hour (OR: 1.41 per 10 units, CI = 1.19-1.66; P ≤ .001) were associated with mortality. Maximum MSI (OR: 1.93 per unit, CI = 1.07-3.48, P = .03) and APACHE III score at 1 hour (OR: 1.29 per 10 units, CI = 1.09-1.53; P = .003) remained significant with mortality in the multivariate analysis. The optimal cutoff point for high MSI and mortality was 1.8. Conclusion: Critically ill patients who demonstrate an elevated MSI within the first 24 hours of ICU admission have a significant mortality risk. Given that MSI is easily calculated at the bedside, clinicians may institute interventions earlier which could improve survival.